KEI and UACT Joint Comments to the NIH Regarding Exclusive License to Syncopation for CAR Therapy

Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) submitted comments to the National Institutes of Health (NIH) on Friday July 9, 2021 regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Monospecific… Continue Reading

KEI and UACT Comments Regarding NIH Exclusive License to Retargeted Therapeutics for Cancer Treatment

Update: The NIH sent a response to our comments, available here. The response fails to address the glaring lack of information available regarding Retargeted Therapeutics. On June 8, 2020, Knowledge Ecology International and the Union for Affordable Cancer Treatment (UACT)… Continue Reading

KEI, UACT, UAEM, and SSW Appeal NIH Grant of Exclusive Licenses on CAR Cancer Therapy to Gilead/Kite

On September 12, 2019, Knowledge Ecology International (KEI), Union for Affordable Cancer Treatment (UACT), Universities Allied for Essential Medicines (UAEM), Social Security Works (SSW), and Clare Love filed an appeal with the National Institutes of Health (NIH). The signatories appealed… Continue Reading